What is NDC 71335-2972?

71335-2972 is the product NDC for Ondansetron, Ondansetron 4 mg/1 tablet, orally disintegrating, listed with the FDA by Bryant Ranch Prepack. It has 8 package NDCs, shown above in 10- and 11-digit form.

Bryant Ranch Prepack, NDC labeler code 71335. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Ondansetron?

190 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Ondansetron NDC 71335-2972 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)71335-2972Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71335-2972Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
71335-2972-1	7133529720171335297201	20 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2972-1)Marketed from Oct 29, 2025
71335-2972-2	7133529720271335297202	60 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2972-2)Marketed from Oct 29, 2025
71335-2972-3	7133529720371335297203	30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2972-3)Marketed from Oct 29, 2025
71335-2972-4	7133529720471335297204	10 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2972-4)Marketed from Oct 29, 2025
71335-2972-5	7133529720571335297205	15 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2972-5)Marketed from Oct 29, 2025
71335-2972-6	7133529720671335297206	6 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2972-6)Marketed from Oct 29, 2025
71335-2972-7	7133529720771335297207	3 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2972-7)Marketed from Oct 29, 2025
71335-2972-8	7133529720871335297208	5 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2972-8)Marketed from Oct 29, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ondansetron
Generic name (nonproprietary): ondansetron
Active ingredients: Ondansetron — 4 mg/1
Dosage form: Tablet, Orally disintegrating
Route: Oral
Labeler: Bryant Ranch PrepackNDC labeler code 71335
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209389
Marketing start: Jun 19, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Serotonin 3 Receptor Antagonists (Mechanism)
Identifiers: Product ID 71335-2972_fdab7199-a313-47a6-9a5a-fc1b27a402d2SPL ID fdab7199-a313-47a6-9a5a-fc1b27a402d2SPL set ID c83821ad-822e-47dc-8108-612312cf3a16RxCUI 104894UNII 4AF302ESOS
Pharmacologic class: Serotonin-3 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471335297201 followed by a unit qualifier and the quantity

Package 71335-2972-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 4, 2026.

Indications (excerpt from the label)

Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. ( 1 ) nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ( 1 ) postoperative nausea and/or vomiting. ( 1 ) Ondansetron orally disintegrating tablets are indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer c…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 71335-2972

What is NDC 71335-2972?: 71335-2972 is the product NDC for Ondansetron, Ondansetron 4 mg/1 tablet, orally disintegrating, listed with the FDA by Bryant Ranch Prepack. It has 8 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Ondansetron.
What is the active ingredient?: Ondansetron.
Who is the labeler?: Bryant Ranch Prepack, NDC labeler code 71335. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Ondansetron?: 190 other product NDCs are listed under this name. See all Ondansetron NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Ondansetron NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Ondansetron	Ondansetron 8 mg/1	Tablet, Orally disintegratingOral	REMEDYREPACK INC.	70518-4685	70518-4685-00
Ondansetron	Ondansetron 8 mg/1	Tablet, Orally disintegratingOral	Preferred Pharmaceuticals Inc.	68788-4133	68788-4133-0168788-4133-03
Ondansetron	Ondansetron hydrochloride 4 mg/5mL	SolutionOral	PAI Holdings, LLC dba PAI Pharma	0121-4882	00121-4882-94
Ondansetron	Ondansetron hydrochloride 4 mg/5mL	SolutionOral	PAI Holdings, LLC dba PAI Pharma	0121-0882	00121-0882-51
Ondansetron	Ondansetron hydrochloride 2 mg/mL	InjectionIntramuscular, Intravenous	JVET PHARMACEUTICALS LLC	86211-115	86211-0115-01
Ondansetron	Ondansetron hydrochloride 4 mg/1	TabletOral	REMEDYREPACK INC.	70518-4588	70518-4588-00
Ondansetron	Ondansetron hydrochloride 2 mg/mL	Injection, SolutionIntramuscular, Intravenous	Hospira, Inc.	0409-2271	00409-2271-25
Ondansetron	Ondansetron 4 mg/1	Tablet, Orally disintegratingOral	AvKARE	42291-457	42291-0457-30
Ondansetron	Ondansetron 8 mg/1	Tablet, Orally disintegratingOral	AvKARE	42291-458	42291-0458-30
Ondansetron	Ondansetron 8 mg/1	Tablet, Orally disintegratingOral	St. Mary's Medical Park Pharmacy	60760-936	60760-0936-10

All 191 Ondansetron NDCs

Other NDCs under ANDA 209389

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209389
Product	Strength	Form · route	Labeler	Product NDC
Ondansetron	Ondansetron 8 mg/1	Tablet, Orally disintegratingOral	Bryant Ranch Prepack	71335-2973
Ondansetron	Ondansetron 8 mg/1	Tablet, Orally disintegratingOral	Bryant Ranch Prepack	71335-2974
Ondansetron	Ondansetron 4 mg/1	Tablet, Orally disintegratingOral	Ipca Laboratories Limited	83980-012
Ondansetron	Ondansetron 8 mg/1	Tablet, Orally disintegratingOral	Ipca Laboratories Limited	83980-013